

RealRate

PHARMACEUTICAL 2021



Salarius Pharmaceuticals Inc. Rank 75 of 402







PHARMACEUTICAL 2021



## RealRate

## Salarius Pharmaceuticals Inc. Rank 75 of 402

The relative strengths and weaknesses of Salarius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Salarius Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Salarius Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 175% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	15,797
Cost of Goods Sold	0
Intangible Assets	8,866
Liabilities, Current	1,854
Liabilities, Non-Current	0
Other Assets	247
Other Compr. Net Income	0
Other Expenses	-259
Other Liabilities	919
Other Net Income	-3.0
Other Revenues	5,412
Property and Equipment	23
Research and Development	6,914
Selling, General and Administrative Expense	6,106

Output Variable	Value in 1000 USD
Assets	24,932
Liabilities	2,773
Expenses	12,761
Revenues	5,412
Stockholders Equity	22,159
Net Income	-7,352
Comprehensive Net Income	-7,352
Economic Capital Ratio	222%

